Pleurisy is an inflammation of the lining of the lungs. When inflamed, the tissue layers rub against each other, causing ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent RSV-associated lower respiratory tract disease (LRTD) in individuals aged 18 to 59 years ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

In recent years, the familiar symptoms of the flu might kick us into reaching for at-home testing kits. But on the eve of the ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

England’s RSV vaccination programme has achieved a 30% reduction in RSV-related hospital admissions among older adults.